Deramciclane inhibits N-methyl-D-aspartate receptor function

Area of Science:

• Neuroscience
• Pharmacology
• Molecular Biology

Background:

• Excitatory amino acids play crucial roles in neurotransmission and neurological disorders.
• Anxiolytic drugs aim to modulate neuronal excitability to alleviate anxiety.
• Understanding the precise mechanisms of anxiolytic action is vital for developing effective treatments.

Purpose of the Study:

• To investigate the effects of the novel anxiolytic deramciclane on excitatory amino acid release.
• To compare deramciclane's impact on transmembrane calcium (Ca2+) ion flux.
• To elucidate the potential role of N-methyl-D-aspartate (NMDA) receptors in deramciclane's anxiolytic properties.

Main Methods:

• Utilized rat cerebrocortical homogenates with resealed plasmalemma fragments and nerve endings.
• Measured the release of [(3)H]D-aspartate, a marker for excitatory amino acid release.
• Assessed transmembrane Ca2+ flux in response to NMDA and (S)-alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor agonists.

Main Results:

• Deramciclane (10 microM) significantly inhibited NMDA-evoked [(3)H]D-aspartate release and Ca2+ flux in the absence of Mg2+.
• Inhibition was not significant for AMPA-evoked release or Ca2+ flux under specific conditions (presence of Mg2+ and cyclothiazide).
• Deramciclane did not inhibit NMDA-evoked release when NMDA receptor antagonists were present, confirming specificity.

Conclusions:

• Deramciclane's anxiolytic effects may stem from the inhibition of presynaptic NMDA receptors.
• The drug specifically modulates NMDA receptor-mediated neurotransmission.
• These findings provide a molecular basis for deramciclane's therapeutic potential in anxiety disorders.